Big Sky Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2014
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
The Ubiquitin System: From Basic Science to Drug Discovery (A2)
Organizer(s) Ingrid E. Wertz and David Komander
January 7—12, 2014
Big Sky Resort • Big Sky, MT USA
Discounted Abstract Deadline: Oct 2, 2013
Abstract Deadline: Oct 24, 2013
Scholarship Deadline: Oct 2, 2013
Discounted Registration Deadline: Nov 7, 2013
Sponsored by Cell Research and Genentech, Inc.
Summary of Meeting:
Ubiquitination, the covalent ligation of target proteins by the 76-amino acid protein ubiquitin, regulates the fate and function of the substrate proteins. Aberrant ubiquitination promotes numerous disease states, but the mechanisms by which the ubiquitin system regulates cellular signaling and pathogenesis remain largely unknown. This meeting will: 1) Highlight recent basic science advances in the field of ubiquitin research; 2) Reveal gaps in our understanding of how the ubiquitin system regulates human disease, and how we can best apply our knowledge to answer these questions; and 3) Update attendees on the efficacy of drugs that target the ubiquitin/proteasome system. Initial plenary sessions will focus on the basic science of the ubiquitin system, including lectures describing ubiquitin modifications and the enzymology of the ubiquitin system. The role of ubiquitination in cellular signaling, with a focus on enzyme sub-classes and specific pathways, will next be explored. Workshops highlighting model systems and technological advances used to investigate the ubiquitin system are also incorporated. The meeting will culminate with sessions focused on the role of the ubiquitin system in human disease and as a drug target. The meeting format will encourage interaction between clinicians, translational researchers and basic scientists with interests ranging from the biophysics to the cellular biology of the ubiquitin system. The anticipated outcomes will be increased understanding of the interrelated roles that the ubiquitin system plays in normal homeostasis and in disease, and of the next steps required to target the ubiquitin system for patient benefit.
View Scholarships/Awards
Ubiquitination, the covalent ligation of target proteins by the 76-amino acid protein ubiquitin, regulates the fate and function of the substrate proteins. Aberrant ubiquitination promotes numerous disease states, but the mechanisms by which the ubiquitin system regulates cellular signaling and pathogenesis remain largely unknown. This meeting will: 1) Highlight recent basic science advances in the field of ubiquitin research; 2) Reveal gaps in our understanding of how the ubiquitin system regulates human disease, and how we can best apply our knowledge to answer these questions; and 3) Update attendees on the efficacy of drugs that target the ubiquitin/proteasome system. Initial plenary sessions will focus on the basic science of the ubiquitin system, including lectures describing ubiquitin modifications and the enzymology of the ubiquitin system. The role of ubiquitination in cellular signaling, with a focus on enzyme sub-classes and specific pathways, will next be explored. Workshops highlighting model systems and technological advances used to investigate the ubiquitin system are also incorporated. The meeting will culminate with sessions focused on the role of the ubiquitin system in human disease and as a drug target. The meeting format will encourage interaction between clinicians, translational researchers and basic scientists with interests ranging from the biophysics to the cellular biology of the ubiquitin system. The anticipated outcomes will be increased understanding of the interrelated roles that the ubiquitin system plays in normal homeostasis and in disease, and of the next steps required to target the ubiquitin system for patient benefit.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
TUESDAY, JANUARY 7
WEDNESDAY, JANUARY 8
THURSDAY, JANUARY 9
FRIDAY, JANUARY 10
SATURDAY, JANUARY 11
SUNDAY, JANUARY 12
Conference Program Print | View meeting in 12 hr (am/pm) time
TUESDAY, JANUARY 7
08:00—09:00
Keynote Address
*
Ingrid E. Wertz,
Genentech, Inc., USA
Raymond J. Deshaies,
Amgen, Inc., USA
Exploiting Protein Homeostasis as a Target for Anti-Cancer Drugs
Exploiting Protein Homeostasis as a Target for Anti-Cancer Drugs
09:00—11:00
Ubiquitin Chains and Modifications
*
Henning Walczak,
University College London, Cancer Institute, UK
David Komander,
Walter and Eliza Hall Institute of Medical Research, Australia
Atypical Ubiquitin Chains
Atypical Ubiquitin Chains
Michael Rape,
University of California, Berkeley, USA
Tumor Suppression by Mitotic Quality Control
Tumor Suppression by Mitotic Quality Control
14:30—16:30
Workshop 1: Technological Advances for Interrogating the Ubiquitin Proteasome System
*
Ingrid E. Wertz,
Genentech, Inc., USA
Marie-Pierre Bousquet,
IPBS - CNRS, University of Toulouse, France
Determination of Proteasome Subcellular Distribution and Molecular Stoichiometry Using Formaldehyde Cross-Linking and Label-Free Quantitative Proteomics
Determination of Proteasome Subcellular Distribution and Molecular Stoichiometry Using Formaldehyde Cross-Linking and Label-Free Quantitative Proteomics
Kevin G. Mark,
University of California, San Francisco, USA
Ubiquitin Ligase Substrate Trapping Identifies an Scf-saf1 Mediated Pathway Targeting Unprocessed Vacuolar/Lysosomal Proteins
Ubiquitin Ligase Substrate Trapping Identifies an Scf-saf1 Mediated Pathway Targeting Unprocessed Vacuolar/Lysosomal Proteins
John S. Schneekloth, Jr.,
NCI, National Institutes of Health, USA
Discovery and Characterization of Small Molecule Probes of Sumoylation Enzymes
Discovery and Characterization of Small Molecule Probes of Sumoylation Enzymes
Monique PC Mulder,
Netherlands Cancer Institute, NKI, Netherlands
Probing Protein Ubiquitination: A Chemical Biology Approach
Probing Protein Ubiquitination: A Chemical Biology Approach
17:00—19:15
Ubiquitin Proteasome System Enzymes: Structural Insights and Biophysical Mechanisms
*
David Komander,
Walter and Eliza Hall Institute of Medical Research, Australia
Brenda A. Schulman,
Max Planck Institute of Biochemistry, Germany
Structural and Mechanistic Studies of Cullin-RING Ligases
Structural and Mechanistic Studies of Cullin-RING Ligases
Eric S. Fischer,
Dana-Farber Cancer Institute, USA
Short Talk: The Structure of an DDB1-CRBN Complex Bound to Thalidomide: Insights into CRL4 Inhibition by Small Molecules
Short Talk: The Structure of an DDB1-CRBN Complex Bound to Thalidomide: Insights into CRL4 Inhibition by Small Molecules
Simin Rahighi,
Stanford University, USA
Short Talk: Structural Basis for the Recognition of a Lys48-Linked Tri-Ubiquitin Chain by the Tandem UIMs of AIRAPL
Short Talk: Structural Basis for the Recognition of a Lys48-Linked Tri-Ubiquitin Chain by the Tandem UIMs of AIRAPL
R. Andrew Byrd,
NCI, National Institutes of Health, USA
Short Talk: Dissecting a Processive Ubiquitination Machine: Dynamic Interplay and Allostery Associated with Secondary Binding Domains of the Ubiquitin RING-Finger Ligase gp78
Short Talk: Dissecting a Processive Ubiquitination Machine: Dynamic Interplay and Allostery Associated with Secondary Binding Domains of the Ubiquitin RING-Finger Ligase gp78
Evan J. Worden,
University of California, Berkeley, USA
Short Talk: Allosteric Regulation and Substrate Specificity of the Proteasome Deubiquitinase Rpn11
Short Talk: Allosteric Regulation and Substrate Specificity of the Proteasome Deubiquitinase Rpn11
08:00—11:00
Ubiquitin-Like Proteins in Cellular Signaling
*
Brenda A. Schulman,
Max Planck Institute of Biochemistry, Germany
Christopher D. Lima,
Memorial Sloan Kettering Cancer Center, USA
Structure and Function in Ub/Ubl Conjugation Pathways
Structure and Function in Ub/Ubl Conjugation Pathways
Marcus Groettrup,
University of Konstanz, Germany
The Ubiquitin-Like Modifier FAT10 Shapes the T Lymphocyte Repertoire
The Ubiquitin-Like Modifier FAT10 Shapes the T Lymphocyte Repertoire
Heran Darwin,
New York University School of Medicine, USA
Latest Developments in the Pup-Proteasome System of Mycobacterium tuberculosis
Latest Developments in the Pup-Proteasome System of Mycobacterium tuberculosis
Sreenivas Gannavaram,
US Food and Drug Administration, USA
Short Talk: Ufm1 Mediated Protein Modification Pathway as Drug Target in the Human Protozoan Parasite Leishmania donovani
Short Talk: Ufm1 Mediated Protein Modification Pathway as Drug Target in the Human Protozoan Parasite Leishmania donovani
Guy S. Salvesen,
Sanford-Burnham Medical Research Institute, USA
Why Is Addition and Removal of SUMO so Dynamic?
Why Is Addition and Removal of SUMO so Dynamic?
17:00—19:15
Regulation of Signaling Pathways by the Ubiquitin Proteasome System
*
Cynthia Wolberger,
Johns Hopkins University School of Medicine, USA
Henning Walczak,
University College London, Cancer Institute, UK
Linear Ubiquitin: New Insight on its Role in Signaling and Development
Linear Ubiquitin: New Insight on its Role in Signaling and Development
Brittney M. Davidge,
Portland State University, USA
Short Talk: The Cul3 Mutant Associated with Hypertension Is an Active Ubiquitin Ligase
Short Talk: The Cul3 Mutant Associated with Hypertension Is an Active Ubiquitin Ligase
Nicolas Bidère,
INSERM, France
Short Talk: A Role for the LUBAC in Antigen Receptor-Mediated NF-kappaB Activation and in Lymphoma Survival
Short Talk: A Role for the LUBAC in Antigen Receptor-Mediated NF-kappaB Activation and in Lymphoma Survival
Arno F. Alpi,
University of Dundee, UK
Short Talk: TRIAD1 and HHARI Modulate the Activity of Distinct Cullin Ring Ligase Complexes
Short Talk: TRIAD1 and HHARI Modulate the Activity of Distinct Cullin Ring Ligase Complexes
Paula M. Oliver,
University of Pennsylvania, USA
Short Talk: Activating Ubiquitin Complexes that Prevent Inflammation
Short Talk: Activating Ubiquitin Complexes that Prevent Inflammation
Ivan Dikic,
Goethe University Medical School, Germany
Regulation of Autophagy by Ubiquitin Networks
Regulation of Autophagy by Ubiquitin Networks
08:00—11:30
Ubiquitin Ligases in Cellular Signaling
*
Michael Rape,
University of California, Berkeley, USA
Rachel Klevit,
University of Washington, USA
How to Modulate Ub E3 Ligase Activity
How to Modulate Ub E3 Ligase Activity
Wenyi Wei,
Beth Israel Deaconess Medical Center, USA
MC1R Deficiency Cooperates with BRaf V600E to Promote Melanomogenesis
MC1R Deficiency Cooperates with BRaf V600E to Promote Melanomogenesis
Wolfgang Dubiel,
Charité - Universitätsmedizin Berlin, Germany
Short Talk: The COP9 Signalosome is Essential for Adipogenesis
Short Talk: The COP9 Signalosome is Essential for Adipogenesis
Ryan Potts,
Amgen, USA
Short Talk: Regulation of Cellular Metabolism by an Oncogenic MAGE-RING E3 Ubiquitin Ligase Targeting AMPK
Short Talk: Regulation of Cellular Metabolism by an Oncogenic MAGE-RING E3 Ubiquitin Ligase Targeting AMPK
Pengbo Zhou,
Weill Cornell Medical College, USA
Short Talk: Recurrent Missense Mutations in the SPOP-CUL3 Ubiquitin Ligase in Prostate Cancer
Short Talk: Recurrent Missense Mutations in the SPOP-CUL3 Ubiquitin Ligase in Prostate Cancer
Matthias Peter,
ETH Zürich, Switzerland
Function and Regulation of CRL Complexes
Function and Regulation of CRL Complexes
14:30—16:30
Workshop 2: Ubiquitin Proteasome System: Insights from Model Systems
*
David Komander,
Walter and Eliza Hall Institute of Medical Research, Australia
*
Adolfo García-Sastre,
Mount Sinai School of Medicine, USA
Regulation of Innate Immunity by TRIM E3 Ligases
Regulation of Innate Immunity by TRIM E3 Ligases
Wim Vandenberghe,
University Hospitals Leuven, Belgium
Identification of a Deubiquitinase that Antagonizes Parkin-Mediated Mitochondrial Ubiquitination and Mitophagy
Identification of a Deubiquitinase that Antagonizes Parkin-Mediated Mitochondrial Ubiquitination and Mitophagy
Michael A. Skinner,
Imperial College London Faculty of Medicine, UK
Interaction of a Fowlpox Virus Modulator of Avian Interferon with the Chicken Cullin-1 and Skp1
Interaction of a Fowlpox Virus Modulator of Avian Interferon with the Chicken Cullin-1 and Skp1
Josua Schinke,
Georg-August University Göttingen, Germany
Interplay between Den1 and CSN Deneddylases and the Phosphatase DipA in Filamentous Fungi
Interplay between Den1 and CSN Deneddylases and the Phosphatase DipA in Filamentous Fungi
Christoph Geisen,
Max Planck Institute for Biology of Ageing, Germany
BLMP-1/BLIMP-1 Is a Novel Substrate of DRE-1/FBXO11 Regulating Developmental Timing
BLMP-1/BLIMP-1 Is a Novel Substrate of DRE-1/FBXO11 Regulating Developmental Timing
17:00—19:00
Deubiquitinase Enzymes in Cellular Signaling
*
Xavier Jacq,
MISSION Therapeutics Ltd., UK
Titia K. Sixma,
Netherlands Cancer Institute, Netherlands
Regulation of DUB Activity by Protein-Protein Interaction
Regulation of DUB Activity by Protein-Protein Interaction
Paul J. Galardy,
Mayo Clinic, USA
Short Talk: USP44 Is an Essential Regulator of Nucleotide Excision Repair
Short Talk: USP44 Is an Essential Regulator of Nucleotide Excision Repair
Nima Mosammaparast,
Washington University in St. Louis, USA
Short Talk: Regulation of DNA Demethylation Repair by the OTUD4 Deubiquitinase
Short Talk: Regulation of DNA Demethylation Repair by the OTUD4 Deubiquitinase
Judy Coulson,
University of Liverpool, UK
Short Talk: The Deubiquitylase Ataxin-3 Restricts PTEN Transcription and PI3K Signaling
Short Talk: The Deubiquitylase Ataxin-3 Restricts PTEN Transcription and PI3K Signaling
Cynthia Wolberger,
Johns Hopkins University School of Medicine, USA
Cross-regulation by Deubiquitinating and E2 Enzymes
Cross-regulation by Deubiquitinating and E2 Enzymes
08:00—11:00
The Ubiquitin Proteasome System as a Drug Target
*
Ivan Dikic,
Goethe University Medical School, Germany
Gwen Nichols,
Hoffmann-LaRoche, USA
Drugging E3 Ligases: MDM2 Antagonist Clinical Development
Drugging E3 Ligases: MDM2 Antagonist Clinical Development
Christopher J. Kirk,
Kezar Life Sciences, USA
Peptide Epoxyketone Proteasome Inhibitors: Tools and Drugs
Peptide Epoxyketone Proteasome Inhibitors: Tools and Drugs
Jennifer A. Johnston,
E3xBio, USA
Short Talk: Identification of Small Molecule Activators of Parkin Protein and Insight into Mechanisms of Enzyme Activation
Short Talk: Identification of Small Molecule Activators of Parkin Protein and Insight into Mechanisms of Enzyme Activation
Namrata D. Udeshi,
Broad Institute of MIT and Harvard, USA
Short Talk: Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3
Short Talk: Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3
Derek F. Ceccarelli,
Samuel Lunenfeld Research Institute, Canada
Short Talk: E2 Enzyme Inhibition by Stabilization of a Low Affinity Interface with Ubiquitin
Short Talk: E2 Enzyme Inhibition by Stabilization of a Low Affinity Interface with Ubiquitin
Xavier Jacq,
MISSION Therapeutics Ltd., UK
Identification of Selective DUB Inhibitors Targeting DDR Deficient Tumors
Identification of Selective DUB Inhibitors Targeting DDR Deficient Tumors
17:00—19:00
The Ubiquitin Proteasome System in Disease
*
Titia K. Sixma,
Netherlands Cancer Institute, Netherlands
Iannis Aifantis,
New York University School of Medicine, USA
Regulation of Leukemia Initiation and Progression by the Ubiquitin System
Regulation of Leukemia Initiation and Progression by the Ubiquitin System
Alain Israël,
Institut Pasteur, France
Ubiquitination in NF-kappaB Signaling
Ubiquitination in NF-kappaB Signaling
Khosrow Rezvani,
University of South Dakota, USA
Short Talk: Ubiquitin-Like (UBX)-Domain-Containing Protein, UBXN2A, Promotes Cell Death by Interfering with the p53-Mortalin2 Interactions in Cancer Cells
Short Talk: Ubiquitin-Like (UBX)-Domain-Containing Protein, UBXN2A, Promotes Cell Death by Interfering with the p53-Mortalin2 Interactions in Cancer Cells
Alexandre Orthwein,
Jewish General Hospital, Canada
Short Talk: Mitotic Inhibition of RNF8/RNF168- Medicated Ubiquitylation Cascade Preserves Genomic Integrity
Short Talk: Mitotic Inhibition of RNF8/RNF168- Medicated Ubiquitylation Cascade Preserves Genomic Integrity
Daniel J. Finley,
Harvard University, USA
Regulation of Proteasome Activity by Ubiquitin Chain Editing
Regulation of Proteasome Activity by Ubiquitin Chain Editing
19:00—19:15
Closing Remarks
David Komander,
Walter and Eliza Hall Institute of Medical Research, Australia
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
